Related Experiment Video
Updated: Feb 24, 2026

Monitoring Protein Aggregation Kinetics In Vivo using Automated Inclusion Counting in Caenorhabditis elegans
Published on: December 17, 2021
[Molecular Pathogenesis of Polyglutamine Diseases]
1Department of Neurology, National Center Hospital, National Center of Neurology and Psychiatry.
Abstract:
Polyglutamine diseases result from gain-of-function mutations. The expanded polyglutamine tracts lead to conformational changes in proteins, resulting in their aggregation. The intermediates including monomers or oligomers, are more toxic than the aggregates to neurons. At the molecular level, protein misfolding, transcriptional dysregulation, deranged calcium homeostasis, impaired cytoskeleton/axonal transport, mitochondrial dysfunction, and RNA toxicity contribute to disease progression. Understanding the underlying pathogenesis facilitates development of therapy for polyglutamine diseases.
Insights
Polyglutamine diseases stem from harmful protein changes caused by genetic mutations. Understanding these molecular issues is key to developing effective treatments for these neurodegenerative conditions.
Area of Science:
- Neuroscience
- Genetics
- Molecular Biology
Background:
- Polyglutamine diseases are a class of neurodegenerative disorders.
- They arise from specific genetic mutations leading to expanded polyglutamine tracts in proteins.
Purpose of the Study:
- To elucidate the molecular pathogenesis of polyglutamine diseases.
- To identify key mechanisms contributing to neuronal toxicity and disease progression.
Main Methods:
- The study reviews molecular mechanisms involved in polyglutamine diseases.
- It focuses on protein conformational changes, aggregation, and intermediate toxicity.
Main Results:
- Expanded polyglutamine tracts induce toxic protein misfolding and aggregation.
- Monomeric or oligomeric intermediates are more neurotoxic than final aggregates.
- Disease progression involves protein misfolding, transcriptional issues, calcium imbalance, impaired axonal transport, mitochondrial dysfunction, and RNA toxicity.
Conclusions:
- Understanding the multifaceted molecular pathology is crucial for therapeutic development.
- Targeting specific molecular pathways may offer effective treatment strategies for polyglutamine diseases.
Related Concept Videos
Translation
Translation Produces the Building Blocks of Life
Proteins are...
Translation
Translation is the process of synthesizing proteins from the genetic information carried by messenger RNA (mRNA). Following transcription, it constitutes the final step in the expression of genes. This process is carried out by ribosomes, complexes of protein and specialized RNA molecules. Ribosomes, transfer RNA (tRNA), and other proteins produce a chain of amino acids—the polypeptide—as the end product of translation.
Translation Produces the Building Blocks of...
Amyloid Fibrils
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
The Proteasome
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. This involves participation of a series of enzymes including— E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
Proteins: From Genes to Degradation
Transcription is the synthesis of RNA...
Lysosomal Hydrolases

